Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2015
At a glance
- Drugs Nintedanib (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma
- Focus Therapeutic Use
- 20 Mar 2014 Planned End Date changed from 1 Mar 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 23 Sep 2013 Planned End Date changed from 1 Jun 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 27 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History